南昌恐惧症去那治南昌上哪家医院治疗焦虑症,南昌到那治发狂好,南昌第十二医院治疗精神科口碑好不好,南昌哪里医治焦虑症好,南昌市那个治躁狂医院比较好,南昌市看癫痫那个医院好,治疗双向情感障碍的南昌医院

CANBERRA, April 1 (Xinhua) -- People who share bongs to smoke marijuana may be at risk of contracting pulmonary tuberculosis (TB) , Australian medical researchers warned on Friday.Dr Michael Hayes and Dr Susan Miles from Calvary Mater Hospital in Newcastle of Australia conducted the research, which centered on three recent TB cases in New South Wales.TB is caused by the bacteria Mycobacterium tuberculosis, which can be contracted by breathing in air droplets coughed from an infected person.The research suggested a link between active TB cases and shared bongs, which is the water pipes commonly used in marijuana smoking.According to Dr Hayes, the three young patients were regular or heavy cannabis users, and more recently there has been a fourth person in the region with similar characteristics had been diagnosed with TB.He said although the three initial cases were not related, there was concern about the high rate of positive contacts among people who had shared bongs with the active cases."Smoking marijuana is a cough-provoking activity and it is usually conducted in a confined environment that is conducive to the spread of the organism," he told Australia Associated Press.

BEIJING, March 3 (Xinhuanet) -- A new study suggested that regular use of painkiller ibuprofen may cut the risk of developing Parkinson's disease, according to Reuters reports.The research findings were published in the online edition of the journal Neurology on Wednesday and later will appear in the print edition on March 8.The study, which followed more than 136,000 U.S. men and women for six years, showed that people who took ibuprofen at least twice a week were 38 percent less likely to develop Parkinson's, a brain disorder that causes tremors and movement problems, compared to those who didn't take the pain reliever so often.Ibuprofen is sold in the U.S. as a non-steroidal anti-inflammatory drug (NSAID). But the study didn't prove that other NSAIDS, like aspirin or naproxen, could also cut the Parkinson's risk."Our study suggests ibuprofen could be a potential neuroprotective agent against Parkinson's," says lead researcher Dr. Xiang Gao from Harvard Medical School, "Protective effects are seen after taking ibuprofen two or more times a week. That's so-called regular use."However, he also warned that no proof has been found that ibuprofen itself can help ward off Parkinson's, and said that it's too early to recommend people to start taking ibuprofen to protect against the disorder.Gao said, "We just see an association, not some causal relationship."Besides, regular ibuprofen use has risks, like stomach bleeding and kidney damage.

SAN FRANCISCO, April 20 (Xinhua) -- Apple Inc. on Wednesday reported record second fiscal quarter results that blow out analysts'expectations, citing strong demands for its products.For its fiscal 2011 second quarter ended on March 26, Apple posted net income of 5.99 billion U.S dollars or 6.4 dollars per share, compared with 3.07 billion, or 3.33 dollars per share a year ago. Its revenue reached 24.67 billion dollars, compare with 13.5 billion in the same period a year earlier.Analysts polled by Thomson Reuters gave an average estimate of 5.35 dollars earning per share on revenue of 23.3 billion."With quarterly revenue growth of 83 percent and profit growth of 95 percent, we're firing on all cylinders," said Steve Jobs, Apple's CEO. "We will continue to innovate on all fronts throughout the remainder of the year."As the most valuable business for the company, Apple sold 18.65 million iPhones in the second quarter, representing 113 percent unit growth over the year-ago quarter. In February, Apple announced that iPhone4 would come on Verizon network, enabling it to attract some 90 million Verizon subscribers to adopt the popular smartphone.The company sold 3.76 million Macs during the quarter, a 28 percent increase over the year-ago quarter, and 9.02 million iPods during the quarter, representing a 17 percent unit decline from the year-ago quarter.The company also sold 4.69 million iPads during the quarter, which is below analysts' projection. Analysts said Apple could have sold more tablets without supply constraints.Wall Street analysts estimated sales of iPad to reach about 6 million in the fiscal second quarter, alongside about 16 million iPhones and 3-4 million Macs.Apple also reported a gross margin of 41.4 percent compared to 41.7 percent in the year-ago quarter. Analyst said the decline of Apple's gross margins can be attributed to two reasons. One reason is the introduction of iPad in 2010 as it is a lower gross margin product than the iPhone. The other is the decline of iPhone margins over years.Supply chain related issues have been analysts' concern in the past quarter as Apple indicated in the Q1 earnings conference call that it could have sold more iPhones and faced some supply related issues. Meanwhile, the Japanese earthquake created more supply related issues for the company as its Japanese suppliers Mitsubishi Gas Chemical and Toshiba are both temporarily shut down to assess damage from the natural disaster.For the third fiscal quarter, Apple CFO Peter Oppenheimer gave an estimated revenue of about 23 billion and profit of 5.03 dollars per share.

CANBERRA, March 23 (Xinhua) -- Up to 45 native species in Western Australia's Kimberley region will die out within 20 years if no action is taken, latest study showed on Wednesday.The Priority Threat Management to Protect Kimberley Wildlife report, released by Commonwealth Scientific and Industrial Research Organization (CSIRO) on Wednesday, was commissioned by the Wilderness Society.The report showed that at present, 20.2 million U.S. dollars a year is spent on conservation efforts in the Kimberley, which is home to an assortment of threatened species.However, the report said even if that money was spent properly, the region would still lose some 31 native animals.The numbers of many more birds, reptiles and mammals, such as the Spotted Tree Monitor and the Western Chestnut Mouse, would dwindle.It called for an immediate cash injection of 96 million U.S. dollars to save creatures like the Golden Bandicoot, the Scaly- Tailed Possum and the Monjon Rock Wallaby from extinction.It will follow by an ongoing investment of 40.43 million U.S. dollars annually in the Kimberley to protect its species, as well as boost plant life, help the climate and conserve indigenous land."This investment is great value," one of the report's six co- authors Hugh Possingham said in a statement released on Wednesday."We can save some of Australia's most iconic mammals and birds at a cost of only about one million U.S. dollars per species per year."

WASHINGTON, April 13 (Xinhua) -- The U.S. Food and Drug Administration (FDA) announced on Wednesday that it has approved the cPAX Aneurysm Treatment System for surgery on brain aneurysms that are difficult to manage because of their size and shape.An aneurysm is a bulge in the wall of a blood vessel, which can rupture as it increases in size, causing hemorrhage or death. Brain aneurysms often produce no symptoms until they grow and press on nerves in the brain, or until they begin to leak blood or rupture.Aneurysms can be repaired in two ways: surgeons can close the base of the aneurysm with a surgical clip, or use a technique commonly known as coiling, in which surgeons use a catheter to thread metallic coils through a blood vessel in the groin and into the blood vessel in the brain that contains the aneurysm. Surgeons then fill the aneurysm with the detachable coils, which block it from circulation and cause blood to clot, effectively destroying the aneurysm.Aneurysms larger than 10 millimeters are difficult to treat with clipping or coiling. The cPAX device system is indicated for use in those brain aneurysms."Like coiling, the cPAX Aneurysm Treatment System is a form of endovascular repair," said Christy Foreman, director of the Office of Device Evaluation in the FDA's Center for Devices and Radiological Health. "But instead of tiny metallic coils, it uses a special polymer material to fill the space within the aneurysm."According to the FDA, the cPAX device system is indicated for use in adults aged 22 and older and should not be used in patients with an active infection or in those in whom anticoagulation and antiplatelet therapy is contraindicated.